TORONTO, Nov. 29, 2017 (GLOBE NEWSWIRE) — Resolve Digital Health Inc. (“Resolve”), a Canadian developer of intelligent medical cannabis delivery devices, has begun protocol design for a series of studies examining the safety and efficacy profiles of Resolve medical cannabis formulations compared to commonly-prescribed oxycodone-based prescription drugs such as OxyContin®/OxyNEO® and Percocet®.
Resolve is designing 12 pain management studies that examine the effectiveness of several opioid products versus Resolve’s Breeze Smart InhalersTM formulations and ecosystem. Breeze products gather real-time dosing data from patients, including medical conditions, prescriptions, family history and lifestyle, in addition to location-based information.
The company’s research program will also explore two additional areas:
- Effectiveness of the Breeze Smart InhalersTM, and the role of medical cannabis, as a first-line and switch therapy in the prevention